Immune Escape from HIV-specific Antibody-dependent Cellular Cytotoxicity (ADCC) Pressure

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2011 Apr 20

PMID 21502492

Citations 93

Authors

Amy W Chung

Gamze Isitman

Marjon Navis

Marit Kramski

Rob J Center

Stephen J Kent

Ivan Stratov

Affiliations

Soon will be listed here.

Abstract

Effective immunity to HIV is poorly understood. In particular, a role for antibody-dependent cellular cytotoxicity (ADCC) in controlling HIV is controversial. We hypothesized that significant pressure from HIV-specific ADCC would result in immune-escape variants. A series of ADCC epitopes in HIV-infected subjects to specific consensus strain HIV peptides were mapped using a flow cytometric assay for natural killer cell activation. We then compared the ADCC responses to the same peptide epitope derived from the concurrent HIV sequence(s) expressed in circulating virus. In 9 of 13 epitopes studied, ADCC antibodies were unable to recognize the concurrent HIV sequence. Our studies suggest ADCC responses apply significant immune pressure on the virus. This result has implications for the induction of ADCC responses by HIV vaccines.

Citing Articles

Polyfunctionality and breadth of HIV-1 antibodies are associated with delayed disease progression.

Grobben M, Bakker M, Schriek A, Levels L, Umotoy J, Tejjani K PLoS Pathog. 2024; 20(12):e1012739.

PMID: 39661636 PMC: 11634010. DOI: 10.1371/journal.ppat.1012739.

Bioorthogonal click labeling of an amber-free HIV-1 provirus for in-virus single molecule imaging.

Ao Y, Grover J, Gifford L, Han Y, Zhong G, Katte R Cell Chem Biol. 2024; 31(3):487-501.e7.

PMID: 38232732 PMC: 10960674. DOI: 10.1016/j.chembiol.2023.12.017.

Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations.

Purcell R, Theisen R, Arnold K, Chung A, Selva K Front Immunol. 2023; 14:1183727.

PMID: 37600816 PMC: 10433199. DOI: 10.3389/fimmu.2023.1183727.

Antibody-dependent cellular cytotoxicity responses and susceptibility influence HIV-1 mother-to-child transmission.

Thomas A, Coote C, Moreau Y, Isaac J, Ewing A, Kourtis A JCI Insight. 2022; 7(9).

PMID: 35324477 PMC: 9090239. DOI: 10.1172/jci.insight.159435.

The HIV Env Glycoprotein Conformational States on Cells and Viruses.

Zhao C, Li H, Swartz T, Chen B mBio. 2022; 13(2):e0182521.

PMID: 35323042 PMC: 9040720. DOI: 10.1128/mbio.01825-21.

References

Peut V, Kent S . Substantial envelope-specific CD8 T-cell immunity fails to control SIV disease. Virology. 2008; 384(1):21-7. DOI: 10.1016/j.virol.2008.11.030. View

Stratov I, Chung A, Kent S . Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol. 2008; 82(11):5450-9. PMC: 2395196. DOI: 10.1128/JVI.01952-07. View

Center R, Wheatley A, Campbell S, Gaeguta A, Peut V, Alcantara S . Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine. 2009; 27(47):6605-12. DOI: 10.1016/j.vaccine.2009.08.016. View

Gomez-Roman V, Patterson L, Venzon D, Liewehr D, Aldrich K, Florese R . Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol. 2005; 174(4):2185-9. DOI: 10.4049/jimmunol.174.4.2185. View

Chung A, Rollman E, Johansson S, Kent S, Stratov I . The utility of ADCC responses in HIV infection. Curr HIV Res. 2008; 6(6):515-9. DOI: 10.2174/157016208786501472. View

Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E . Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A. 2005; 102(8):2886-91. PMC: 549494. DOI: 10.1073/pnas.0409872102. View

Goonetilleke N, Liu M, Salazar-Gonzalez J, Ferrari G, Giorgi E, Ganusov V . The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med. 2009; 206(6):1253-72. PMC: 2715063. DOI: 10.1084/jem.20090365. View

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R . Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361(23):2209-20. DOI: 10.1056/NEJMoa0908492. View

Karnasuta C, Paris R, Cox J, Nitayaphan S, Pitisuttithum P, Thongcharoen P . Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine. 2005; 23(19):2522-9. DOI: 10.1016/j.vaccine.2004.10.028. View

10.

Chung A, Rollman E, Center R, Kent S, Stratov I . Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol. 2009; 182(2):1202-10. DOI: 10.4049/jimmunol.182.2.1202. View

11.

Dinges W, Richardt J, Friedrich D, Jalbert E, Liu Y, Stevens C . Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J Virol. 2010; 84(9):4461-8. PMC: 2863751. DOI: 10.1128/JVI.02438-09. View

12.

Fernandez C, Stratov I, De Rose R, Walsh K, Dale C, Smith M . Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol. 2005; 79(9):5721-31. PMC: 1082732. DOI: 10.1128/JVI.79.9.5721-5731.2005. View

13.

Richman D, Wrin T, Little S, Petropoulos C . Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003; 100(7):4144-9. PMC: 153062. DOI: 10.1073/pnas.0630530100. View

14.

Gomez-Roman V, Florese R, Patterson L, Peng B, Venzon D, Aldrich K . A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods. 2005; 308(1-2):53-67. DOI: 10.1016/j.jim.2005.09.018. View

15.

Troyer R, McNevin J, Liu Y, Zhang S, Krizan R, Abraha A . Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 2009; 5(4):e1000365. PMC: 2659432. DOI: 10.1371/journal.ppat.1000365. View

16.

Nandi A, Lavine C, Wang P, Lipchina I, Goepfert P, Shaw G . Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology. 2009; 396(2):339-48. PMC: 2789835. DOI: 10.1016/j.virol.2009.10.044. View

17.

Leslie A, Pfafferott K, Chetty P, Draenert R, Addo M, Feeney M . HIV evolution: CTL escape mutation and reversion after transmission. Nat Med. 2004; 10(3):282-9. DOI: 10.1038/nm992. View

18.

Fernandez C, Smith M, Batten C, De Rose R, Reece J, Rollman E . Vaccine-induced T cells control reversion of AIDS virus immune escape mutants. J Virol. 2007; 81(8):4137-44. PMC: 1866163. DOI: 10.1128/JVI.02193-06. View

19.

Stratov I, Dale C, Chea S, McCluskey J, Kent S . Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol. 2005; 79(12):7728-37. PMC: 1143690. DOI: 10.1128/JVI.79.12.7728-7737.2005. View

20.

Peut V, Kent S . Utility of human immunodeficiency virus type 1 envelope as a T-cell immunogen. J Virol. 2007; 81(23):13125-34. PMC: 2169096. DOI: 10.1128/JVI.01408-07. View